466 related articles for article (PubMed ID: 16449087)
1. Inpatient initiation of buprenorphine maintenance vs. detoxification: can retention of opioid-dependent patients in outpatient counseling be improved?
Caldiero RM; Parran TV; Adelman CL; Piche B
Am J Addict; 2006; 15(1):1-7. PubMed ID: 16449087
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
Amato P
Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
[TBL] [Abstract][Full Text] [Related]
4. Treatment completion on an inpatient detoxification unit: impact of a change to sublingual buprenorphine-naloxone.
Soeffing JM; Rastegar DA
J Subst Abuse Treat; 2007 Dec; 33(4):401-4. PubMed ID: 17400414
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.
Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V
Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
[TBL] [Abstract][Full Text] [Related]
7. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.
Woody GE; Poole SA; Subramaniam G; Dugosh K; Bogenschutz M; Abbott P; Patkar A; Publicker M; McCain K; Potter JS; Forman R; Vetter V; McNicholas L; Blaine J; Lynch KG; Fudala P
JAMA; 2008 Nov; 300(17):2003-11. PubMed ID: 18984887
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years.
Fiellin DA; Moore BA; Sullivan LE; Becker WC; Pantalon MV; Chawarski MC; Barry DT; O'Connor PG; Schottenfeld RS
Am J Addict; 2008; 17(2):116-20. PubMed ID: 18393054
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
Webster L; Hjelmström P; Sumner M; Gunderson EW
J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
[TBL] [Abstract][Full Text] [Related]
10. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J
Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526
[TBL] [Abstract][Full Text] [Related]
11. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.
Amass L; Ling W; Freese TE; Reiber C; Annon JJ; Cohen AJ; McCarty D; Reid MS; Brown LS; Clark C; Ziedonis DM; Krejci J; Stine S; Winhusen T; Brigham G; Babcock D; Muir JA; Buchan BJ; Horton T
Am J Addict; 2004; 13 Suppl 1(Suppl 1):S42-66. PubMed ID: 15204675
[TBL] [Abstract][Full Text] [Related]
12. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films.
Strain EC; Harrison JA; Bigelow GE
Clin Pharmacol Ther; 2011 Mar; 89(3):443-9. PubMed ID: 21270789
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.
Orman JS; Keating GM
Drugs; 2009; 69(5):577-607. PubMed ID: 19368419
[TBL] [Abstract][Full Text] [Related]
14. Less pain, more gain: buprenorphine-naloxone and patient retention in treatment.
Renzelli CM; Capretto NA
J Addict Dis; 2006; 25(3):97-104. PubMed ID: 16956874
[TBL] [Abstract][Full Text] [Related]
15. Sleep-disordered breathing in patients with opioid use disorders in long-term maintenance on buprenorphine-naloxone: A case series.
DeVido J; Connery H; Hill KP
J Opioid Manag; 2015; 11(4):363-6. PubMed ID: 26312963
[TBL] [Abstract][Full Text] [Related]
16. Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment.
Mokri A; Chawarski MC; Taherinakhost H; Schottenfeld RS
Addiction; 2016 May; 111(5):874-82. PubMed ID: 26639678
[TBL] [Abstract][Full Text] [Related]
17. Tramadol versus buprenorphine for the management of acute heroin withdrawal: a retrospective matched cohort controlled study.
Threlkeld M; Parran TV; Adelman CA; Grey SF; Yu J
Am J Addict; 2006; 15(2):186-91. PubMed ID: 16595358
[TBL] [Abstract][Full Text] [Related]
18. Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.
McDermott KA; Griffin ML; Connery HS; Hilario EY; Fiellin DA; Fitzmaurice GM; Weiss RD
J Clin Psychiatry; 2015 Feb; 76(2):189-94. PubMed ID: 25562462
[TBL] [Abstract][Full Text] [Related]
19. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.
Comer SD; Sullivan MA; Vosburg SK; Manubay J; Amass L; Cooper ZD; Saccone P; Kleber HD
Addiction; 2010 Apr; 105(4):709-18. PubMed ID: 20403021
[TBL] [Abstract][Full Text] [Related]
20. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence.
Clay E; Khemiri A; Zah V; Aballéa S; Ruby J; Asche CV
J Med Econ; 2014 Sep; 17(9):626-36. PubMed ID: 24841329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]